Sustained autoimmune mechanisms in dermatomyositis

Journal of Pathology

Volumn 233, Issue 3, 2014, Pages 215-216

  Greenberg, Steven A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

dermatomyositis; innate immune system; type 1 interferon

Indexed keywords

ALPHA INTERFERON; INTERFERON; TYPE 1 INTERFERON-INDUCIBLE GENE; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; DERMATOMYOSITIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; INNATE IMMUNITY; INTERFERON PRODUCTION; MOLECULAR MECHANICS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

DERMATOMYOSITIS; INNATE IMMUNE SYSTEM; TYPE 1 INTERFERON;

DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNITY, INNATE; MALE; MUSCLE FIBERS, SKELETAL; SIGNAL TRANSDUCTION;

EID: 84902320497     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4355     Document Type: Review

References (15)

1. Lam C, Vleugels RA,. Management of cutaneous dermatomyositis. Dermatol Ther 2012; 25: 112-134.
2. Hundley JL, Carroll CL, Lang W, et al., Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006; 54: 217-220.
3. Greenberg SA, Fiorentino D,. Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle. Br J Dermatol 2009; 160: 464-465.
4. Greenberg SA, Sanoudou D, Haslett JN, et al., Molecular profiles of inflammatory myopathies. Neurology 2002; 59: 1170-1182.
5. + children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002; 168: 4154-4163.
6. Greenberg SA, Pinkus JL, Pinkus GS, et al., Interferon-α/β- mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57: 664-678.
7. Walsh RJ, Kong SW, Yao Y, et al., Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthr Rheum 2007; 56: 3784-3792.
8. Salajegheh M, Kong SK, Pinkus JL, et al., Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 2010; 67: 53-63.
9. Wong D, Kea B, Pesich R, et al., Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PloS One 2012; 7: e29161.
10. Haller O, Kochs G,. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011; 31: 79-87.
11. Knight E, Jr., Antiviral and cell growth inhibitory activities reside in the same glycoprotein of human fibroblast interferon. Nature 1976; 262: 302-303.
12. Sheppard P, Kindsvogel W, Xu W, et al., IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68.
13. Suárez-Calvet X, Gallardo E, Nogales-Gadea G, et al., Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis. J Pathol 2014; 233: 258-268.
14. Nakashima R, Imura Y, Kobayashi S, et al., The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxf) 2010; 49: 433-440.
15. Liao AP, Salajegheh M, Nazareno R, et al., Interferon-β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis 2011; 70: 831-6.